Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years

INTRODUCTION: Most patients with HER2-positive breast cancer receive chemotherapy and trastuzumab. Data from adjuvant trials have shown that the combination of docetaxel, carboplatin and weekly trastuzumab (TCH) is well tolerated and as effective as anthracycline-containing regimes. Previous investi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Care (Basel)
Main Authors: Kolberg, Hans-Christian, Akpolat-Basci, Leyla, Stephanou, Miltiades, Aktas, Bahriye, Hannig, Carla Verena, Liedtke, Cornelia
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger GmbH 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5123029/
https://ncbi.nlm.nih.gov/pubmed/27920624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000452079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados